
Needle-Free Revolution: How ARS Pharma’s Neffy is Changing Allergy Care
In a significant leap forward for medtech innovation, ARS Pharmaceuticals has secured FDA approval for Neffy 1 mg, the first needle-free epinephrine nasal spray designed
Discover cutting-edge medical technology that’s shaping the future of healthcare. From wearable health tech and AI-driven diagnostics to life-saving medical devices, find out how medtech innovations are improving clinical outcomes and enhancing patient care.
In a significant leap forward for medtech innovation, ARS Pharmaceuticals has secured FDA approval for Neffy 1 mg, the first needle-free epinephrine nasal spray designed
Key Takeaways: Wearable devices are advancing from fitness tracking to clinical-grade health monitoring. Innovations include devices for chronic disease management, remote patient monitoring, and mental
Overview: A look at the major biotech, medtech, and pharma conferences in 2025. Key Details: Dates, locations, and highlights from each event. Industry Impact: Why
Quick Summary •FDA Clearance: LumiThera’s Valeda system becomes the first FDA-approved treatment for dry age-related macular degeneration (AMD). •Technology: Utilizes photobiomodulation (PBM) therapy to stimulate
Quick Summary •CMS Coverage: CMS has approved Medtronic’s renal denervation procedure for patients with resistant hypertension. •Innovation: This minimally invasive treatment targets kidney nerves to
Quick Summary Approval: The Centers for Medicare & Medicaid Services (CMS) now covers Medtronic’s renal denervation procedure for hypertension. Treatment: Renal denervation targets nerves in
Quick Summary FDA Approval: The FDA has granted clearance for LumiThera’s Valeda system, the first treatment approved for dry age-related macular degeneration (AMD). Technology: The
Quick Summary Acquisition Value: $350 million Strategic Focus: Expanding Hologic’s gynecology portfolio, specifically in minimally invasive surgical solutions. Impact: Strengthens Hologic’s offering in women’s health
Quick Summary IPO Details: Ceribell launched its IPO at $17 per share, closing above $25. Technology Focus: Portable EEG system for emergency and ICU use.
Quick Summary Focus: Onward Medical licenses a brain-computer interface (BCI) chip from CEA-Clinatec. Goal: Enable spinal cord injury patients to regain communication between brain and